ProCE Banner Activity

Phase III MEDALIST: Erythroid Maturation Agent Luspatercept in Very Low– to Intermediate-Risk Myelodysplastic Syndrome With Ring Sideroblasts

Slideset Download
Conference Coverage
Luspatercept significantly reduced transfusion burden and improved hemoglobin levels compared with placebo for transfusion-dependent anemia in patients with lower-risk myelodysplastic syndrome with ring sideroblasts.

Released: December 17, 2018

Expiration: December 16, 2019

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Celgene

Dova Pharmaceuticals

Gilead Text

Incyte

Janssen Biotech Pharmacyclics Abbvie

Jazz Pharmaceuticals, Inc.

Novartis Pharmaceuticals Corporation

Seagen

Takeda Oncology